hr combined with folfox4 for hcc with pvtt

Conditions: Hepatocellular Carcinoma

Summary: hepatocellular carcinoma (hcc) is the sixth most common cancer and the third most frequent cause of cancer death worldwide. hepatic resection (hr) is the conventional ''curative'' treatment for hcc. in both the european and the united states proposed guidelines for hcc, hr is recommended only for patients with preserved liver function and with early stage hcc. unfortunately, because of tumor multifocality, portal vein invasion, and underlying advanced cirrhosis, only 10% to 30% of hccs are amenable to such a ''curative'' treatment at the time of diagnosis. transarterialchemoembolization (tace) has become the most popular palliative treatment for patients with unresectable hcc, and it is no longer considered as a contraindication to hcc with portal vein tumor thrombus (pvtt). unfortunately, the long-term outcomes are generally poor for hcc treated with tace, especially for hcc with pvtt. to improve on the results of treatment of hcc with pvtt, attempts have been made to perform hr for these patients. hcc with pvtt remains a contraindication to liver transplantation because of the high rate of tumor recurrence, and because of the severe shortage of donor organs. hr remains the only therapeutic option that may still offer a chance of cure. with advances in surgical techniques, it has become feasible to remove all gross tumors, including pvtt, which has extended to the main portal vein, safely by surgery. more hcc with pvtt, which previously were considered as unresectable, have become resectable.recent studies have even shown favorable long-term survival outcomes of hr in well-selected cases of hcc with pvtt. however, the recurrence rate after hr for pvtt is still high and the prognosis for patients with hcc with pvtt is very poor. systemic chemotherapy is considered to be one of the main treatments for malignant tumors. hcc is known to be highly refractory to conventional systemic chemotherapy because of its heterogeneity and multiple etiologies. before the advent of the molecular-targeted agent sorafenib, which has subsequently become the standard of care, no standard systemic drug or treatment regimen had shown an obvious survival benefit in hcc. nowadays, there is no systemic chemotherapy regimen had been definitively recommended as the standard for treating hcc. clinical activity of several regimens containing oxaliplatin (oxa) in advanced hcc had been demonstrated in phase ii studies. in a phase ii study of the folfox4 (infusional fluorouracil \[fu\], leucovorin\[lv\], and oxa) regimen in chinese patients with hcc, median overall survival (os) was 12.4 months, mean time to progression was 2.0 months, and the response rate (rr) was 18.2%. the safety profile was acceptable. recently, the results of a phase ⅲ randomize study showed that folfox4 served as palliative chemotherapy can induce higher overall survival, progression-free survival and response rate comparing to doxorubicin in patients with advanced hepatocellular carcinoma from asia. the safety data was also acceptable.so the investigators' hypothesis is that post-surgery folfox4 can reduce high recurrence rate after hr for hcc with pvtt. the aim of this open-label, single prospective study is to evaluate the efficacy and safety of hr combined with folfox4 systemic chemotherapy for patients with hcc with pvtt.


Eligibility criteria:
inclusion criteria: 1. age between 18 and 75 years; 2. presence of pvtt on imaging, except pvtt extending to involve the superior mesenteric vein 3. ecog status 0; 4. resectable disease( defined as the possibility of completely removing all gross tumors and retaining a sufficient liver remnant to sustain life) exclusion criteria: 1. the presence of extrahepatic spread on imaging; 2. a child-pugh class c liver cirrhosis, or icg-r15 \>30%, or evidence of hepatic decompensation including ascites, esophageal, or gastric variceal bleeding or hepatic encephalopathy; 3. an american society of anesthesiologists (asa) score ≥3.